Zim Laboratories Files Annual Report for FY 2025-26

Zim Laboratories Ltd has filed its Annual Report for the Financial Year 2025-26, as per SEBI regulations. The report details the company's performance, strategic priorities for FY27, and its focus on patient-centric drug delivery solutions using Novel Drug Delivery Techniques. Key highlights include addressing EU-GMP remediation, strengthening quality systems, and advancing its differentiated product portfolio. The company also reported strengthening human resources and leadership capabilities with strategic hires in key positions to support global ambitions. The Annual Report is available on the company's website.